IL13RA2 and glioblastoma: In targeting glioblastoma cells, CAR-T cells modified with a targeted-quadruple-mutant of IL13 was combined with fluorescent therapeutic NPs and targeted to IL13Rα2 overexpressed glioblastoma cells.